Search

Author/Creator Francois, S.

1. REDUCED INTENSITY (FB2) VS REDUCED TOXICITY MYELOABLATIVE (FB3‐4) FLUDARABINE/BUSULFAN‐BASED CONDITIONING REGIMENS FOR NON‐HODGKIN LYMPHOMA (NHL) ALLOGRAFTED PATIENTS. (June 2017)

Authors:
Le Bourgeois, A.; Labopin, M.; Blaise, D.; Ceballos, P.; Vigouroux, S.; Peffault De Latour, R.; Suarez, F.; Bulabois, C.; Bay, J.; Chantepie, S.; Deconinck, E.; Daguindau, E.; Contentin, N.; Yakoub‐Agha, I.; Cornillon, J.; Francois, S.; Turlure, P.; Charbonnier, A.; Rohrlich, P.; N'Guyen, S.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
193
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. S236: RANDOMIZED MULTICENTER PHASE III STUDY OF HAPLO VERSUS HLA-MATCHED UNRELATED DONOR (UD) ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO HSCT) FOR PATIENTS OLDER THAN 55 YEARS. (23rd June 2022)

Authors:
Harbi, S.; Boher, J.-M.; Forcade, E.; Chevallier, P.; Peffault De Latour, R.; Malard, F.; Francois, S.; Charbonnier, A.; Hermet, E.; Bulabois, C. E.; Huynh, A.; Berceanu, A.; Cluzeau, T.; Rubio, M. T.; Furst, S.; devillier, R.; Mohty, M.; Blaise, D.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
137
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search